Drugs / SB-705498
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01673529 | Jul → Oct 2012 | atopic eczema | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00907933 | Nov 2008 → Feb 2009 | rhinitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00731250 | Jul 2008 → Mar 2009 | rhinitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT01424397 | Apr → Jul 2011 | rhinitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01424514 | Dec 2010 → Apr 2011 | rhinitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00461682 | Jan → Sep 2007 | irritable bowel syndrome | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT00269022 | Jan 2006 → ? | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00281684 | Dec 2005 → Oct 2007 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT01476098 Comparator | Apr → Dec 2011 | rhinitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01439308 Comparator | Dec 2009 → Apr 2010 | rhinitis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB-705498 | “A Multi-centre, Randomised, Single Blind, Placebo Controlled, Parallel Group Study to Examine the Effect of Single Doses of SB-705498, a TRPV1 Receptor Antagonist, on Pain...” NCT00281684 ↗ |
| Known as | GSK705498 | ChEMBL registry synonym — accepted as the source's own label CHEMBL207433 ↗ |
| Action | Inhibit | “inhibition of TRPV1 with SB-705498 can both prevent and reverse established central sensitisation.” NCT00269022 ↗ |
| Modality | Small molecule | — CHEMBL207433 ↗ |
| Route | Oral | “Eligible participants received a single dose of SB705498 400 milligram (mg) capsules (2 x 200 mg capsules plus 2 placebo capsules) via oral route and were followed up to a...” NCT00281684 ↗ |
| Target | TRPV1 | “TRPV1 receptor antagonist” NCT00269022 ↗ |